Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Reconsideration of Anticholinesterase Therapeutic Strategies against Alzheimer’s Disease
Huan Wang, Haiyan Zhang
ACS Chemical Neuroscience (2018) Vol. 10, Iss. 2, pp. 852-862
Closed Access | Times Cited: 113

Showing 1-25 of 113 citing articles:

Role of Cholinergic Signaling in Alzheimer’s Disease
Zhi-Ru Chen, Jiabao Huang, Shu‐Long Yang, et al.
Molecules (2022) Vol. 27, Iss. 6, pp. 1816-1816
Open Access | Times Cited: 384
Molecular Hybridization as a Tool for Designing Multitarget Drug Candidates for Complex Diseases
Viktoriya Ivasiv, Claudia Albertini, Ana Elisa Gonçalves, et al.
Current Topics in Medicinal Chemistry (2019) Vol. 19, Iss. 19, pp. 1694-1711
Closed Access | Times Cited: 268
Advances in Alzheimer's disease: A multifaceted review of potential therapies and diagnostic techniques for early detection
Monika Sharma, Pankaj Pal, Sukesh Kumar Gupta
Neurochemistry International (2024) Vol. 177, pp. 105761-105761
Closed Access | Times Cited: 16
Developments with multi-target drugs for Alzheimer’s disease: an overview of the current discovery approaches
Juan F. González, Andrés R. Alcántara, A. Doadrio, et al.
Expert Opinion on Drug Discovery (2019) Vol. 14, Iss. 9, pp. 879-891
Closed Access | Times Cited: 81
Dual-target compounds for Alzheimer's disease: Natural and synthetic AChE and BACE-1 dual-inhibitors and their structure-activity relationship (SAR)
João P. S. Ferreira, Hélio M. T. Albuquerque, Susana M. Cardoso, et al.
European Journal of Medicinal Chemistry (2021) Vol. 221, pp. 113492-113492
Closed Access | Times Cited: 60
Visuo‐spatial learning and memory impairments in the 5xFAD mouse model of Alzheimer's disease: Effects of age, sex, albinism, and motor impairments
Timothy P. O’Leary, Richard E. Brown
Genes Brain & Behavior (2022) Vol. 21, Iss. 4
Open Access | Times Cited: 42
8-Hydroxyquinolylnitrones as multifunctional ligands for the therapy of neurodegenerative diseases
Damijan Knez, Daniel Diez‐Iriepa, Mourad Chioua, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 13, Iss. 5, pp. 2152-2175
Open Access | Times Cited: 26
Rationally Designed Functionalization of Single‐Walled Carbon Nanotubes for Real‐Time Monitoring of Cholinesterase Activity and Inhibition in Plasma
Srestha Basu, Adi Hendler‐Neumark, Gili Bisker
Small (2024) Vol. 20, Iss. 24
Open Access | Times Cited: 12
Alzheimer’s disease: a review on the current trends of the effective diagnosis and therapeutics
Aimi Syamima Abdul Manap, Reema Almadodi, Shirin Sultana, et al.
Frontiers in Aging Neuroscience (2024) Vol. 16
Open Access | Times Cited: 8
Discovery of pyrazoline analogs as multi-targeting cholinesterase, β-secretase and Aβ aggregation inhibitors through lead optimization strategy
Nilesh Gajanan Bajad, Jatin Jangra, T A Gajendra, et al.
International Journal of Biological Macromolecules (2025), pp. 140436-140436
Closed Access | Times Cited: 1
Isoquinoline alkaloids from the roots of Zanthoxylum rigidum as multi-target inhibitors of cholinesterase, monoamine oxidase A and Aβ1-42 aggregation
Erika Plazas, Stefanie Hagenow, Mónica Constanza Ávila Murillo, et al.
Bioorganic Chemistry (2020) Vol. 98, pp. 103722-103722
Closed Access | Times Cited: 50
Therapeutic potential of quinazoline derivatives for Alzheimer's disease: A comprehensive review
Zahra Haghighijoo, Leila Zamani, Fatemeh Moosavi, et al.
European Journal of Medicinal Chemistry (2021) Vol. 227, pp. 113949-113949
Closed Access | Times Cited: 48
Acetylcholinesterase inhibitors for the treatment of Alzheimer’s disease – a patent review (2016–present)
Martina Bortolami, Daniele Rocco, Antonella Messore, et al.
Expert Opinion on Therapeutic Patents (2021) Vol. 31, Iss. 5, pp. 399-420
Closed Access | Times Cited: 46
Multiple roles of fucoxanthin and astaxanthin against Alzheimer's disease: Their pharmacological potential and therapeutic insights
Najmeh Oliyaei, Marzieh Moosavi‐Nasab, Nader Tanideh, et al.
Brain Research Bulletin (2022) Vol. 193, pp. 11-21
Open Access | Times Cited: 35
Probing Fluorinated Motifs onto Dual AChE-MAO B Inhibitors: Rational Design, Synthesis, Biological Evaluation, and Early-ADME Studies
Mariagrazia Rullo, Marco Cipolloni, Marco Catto, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 5, pp. 3962-3977
Closed Access | Times Cited: 32
Cholinesterase Inhibitors from an Endophytic Fungus Aspergillus niveus Fv-er401: Metabolomics, Isolation and Molecular Docking
Ahmed A. Hamed, Riham A. El‐Shiekh, Osama G. Mohamed, et al.
Molecules (2023) Vol. 28, Iss. 6, pp. 2559-2559
Open Access | Times Cited: 19
Enhancing the Therapeutic Effect in Alzheimer's Disease Drugs: The role of Polypharmacology and Cholinesterase inhibitors
M. Margarida Martins, Paula S. Branco, Luı́sa M. Ferreira
ChemistrySelect (2023) Vol. 8, Iss. 10
Open Access | Times Cited: 18
Development of multi-targetable chalcone derivatives bearing N-aryl piperazine moiety for the treatment of Alzheimer's disease
Nilesh Gajanan Bajad, Ravi Bhushan Singh, Gajendra T.A., et al.
Bioorganic Chemistry (2024) Vol. 143, pp. 107082-107082
Closed Access | Times Cited: 6
Dual-target inhibitors of cholinesterase and GSK-3β to modulate Alzheimer’s disease
Junqiu He, Kin Yip Tam
Drug Discovery Today (2024) Vol. 29, Iss. 4, pp. 103914-103914
Closed Access | Times Cited: 6
N-alkylpiperidine carbamates as potential anti-Alzheimer’s agents
Urban Košak, Nika Strašek, Damijan Knez, et al.
European Journal of Medicinal Chemistry (2020) Vol. 197, pp. 112282-112282
Closed Access | Times Cited: 45
Amyloid-β and tau aggregation dual-inhibitors: A synthetic and structure-activity relationship focused review
Daniela Malafaia, Hélio M. T. Albuquerque, Artur M. S. Silva
European Journal of Medicinal Chemistry (2021) Vol. 214, pp. 113209-113209
Closed Access | Times Cited: 39
Determinants of approved acetylcholinesterase inhibitor response outcomes in Alzheimer’s disease: relevance for precision medicine in neurodegenerative diseases
Simone Lista, Andrea Vergallo, Stefan Teipel, et al.
Ageing Research Reviews (2022) Vol. 84, pp. 101819-101819
Open Access | Times Cited: 25
Advances of metallodrug-amyloid β aggregation inhibitors for therapeutic intervention in neurodegenerative diseases: Evaluation of their mechanistic insights and neurotoxicity
Huzaifa Yasir Khan, Azeem Ahmad, Md Nadir Hassan, et al.
Coordination Chemistry Reviews (2023) Vol. 501, pp. 215580-215580
Closed Access | Times Cited: 15
Drug Development for Alzheimer’s and Parkinson’s Disease: Where Do We Go Now?
Lisa Sequeira, Sofia Benfeito, Carlos Fernandes, et al.
Pharmaceutics (2024) Vol. 16, Iss. 6, pp. 708-708
Open Access | Times Cited: 5
Evaluation of 3,4-diethoxy substituted thioureas and their thiazole derivatives as potent anti-Alzheimer's agents: Synthesis, DFT, biological activity and molecular modeling investigations
Mahnoor Mahmood, Zahid Hussain, Muhammad Zahid Ullah, et al.
Journal of Molecular Structure (2024) Vol. 1314, pp. 138760-138760
Closed Access | Times Cited: 5
Page 1 - Next Page

Scroll to top